Combination Treatment Approved for Advanced Hepatocellular Carcinoma
On May 29, 2020, the FDA approved the monoclonal antibody atezolizumab in combination with the vascular endothelial growth inhibitor factor bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. The approval of this combination was based on the results from the multicenter, open-label, phase III IMbrave150 study. Read more.

Enzalutamide Expands Prostate Cancer Overall Survival
According to the final results of the phase III PROSPER trial presented at the ASCO20 Virtual Scientific Program during the 2020 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine, the addition of enzalutamide to androgen deprivation therapy significantly prolonged overall survival among men with nonmetastatic castration-resistant prostate cancer. Read more. 

Novel Triple Therapy Improves Multiple Myeloma Outcomes
The initial results of the phase III BOSTON trial presented during the ASCO20 Virtual Scientific Program revealed that once-weekly selinexor, bortezomib, and dexamethasone—compared with twice-weekly bortezomib and dexamethasone—met the primary endpoint, significantly enhancing progression-free survival and overall response rate in patients with multiple myeloma. Read more.